about
First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors.The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.Induction of HER2 Immunity in Outbred Domestic Cats by DNA Electrovaccination.Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II TrialVenous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer.Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [(18)F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer.Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study.Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin.Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinomaAcademic Cancer Center Phase I Program Development.Characterizing the outcomes of metastatic papillary renal cell carcinoma.Pharmacokinetics of carfilzomib in patients with advanced malignancies and varying degrees of hepatic impairment: an open-label, single-arm, phase 1 study.Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy.Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer.Radium-223 in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer.Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: A Retrospective International Study of Invasive/advanced cancer of the urothelium (RISC).Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer.Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.A novel cross-talk between CXCR4 and PI4KIIIα in prostate cancer cellsDevelopment of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder CancerExceptional pathologic complete response achieved with androgen deprivation and docetaxel therapy in Gleason 10 prostate cancerPerception of cure among patients with metastatic genitourinary cancer initiating immunotherapyEfficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor TrialCurrent State of Systemic Therapies for Advanced Renal Cell CarcinomaImpact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial CarcinomaTherapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of TreatmentInfigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA resultsAvelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trialResults of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid FeaturesTumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophagesCancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single InstitutionPhase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer
P50
Q33438286-2151C2FC-A0EE-4652-8E07-ACF1C36C6E9DQ34081616-D31DDC9E-8215-4322-9A91-1B6C815840FFQ35157412-7D274CB2-EB3D-43D8-BC98-0DDE2979642BQ35561464-8AD43D4E-12FA-4E6C-9EFC-8D6662FBE281Q35602518-8F9E94D3-56C6-4EE1-8B08-11725E7EAD10Q35815995-6C591BF8-68E3-45B3-9602-DDFDB6FCB1C4Q36726204-C53826EE-4115-4245-9149-523D0967E19FQ37609437-B11177EC-9196-4127-B47D-E134438FEA5BQ38195723-0ED14B9D-5B95-4127-B802-51D5FB201014Q38650264-CB13DAC7-52BE-4991-A72F-E682D3EF1193Q38746311-ED9C7391-3C2E-4F05-82FF-865AC07913FCQ38746778-3D72E8D6-DC57-4E61-9F25-4918FC3D62F3Q38865046-682E62B9-4EC7-400B-BABA-9D10660CA9E8Q39176728-998B162E-233B-41EC-A67F-F4C20C1B98D6Q40294732-0FFC1959-2278-4492-9B74-ED68DED1F38BQ41768357-640F7114-56C9-4CCA-9C0D-00AE6B0B2E9BQ42046541-6BFB9F01-C3AA-465E-BDD2-0196C0D3DBB5Q42172414-F75B85AB-3022-4C22-BEE9-B6F74E2052EEQ42281121-5BAE364E-AA5F-4E57-A35A-C8F24922ED81Q42682360-47BC99BA-05C7-4B0D-94EF-DEEA6D9D8EC7Q46290452-32F730BC-F327-42DD-8C83-361B31A995EEQ46983422-E396CF6E-B2F7-4009-9A7B-BA85D3C7268EQ47566387-87C53EF6-CEB0-480C-9BC5-267A17232A2DQ49721662-D9296DD6-352E-4EDA-BF47-69E31B8E92E9Q50030031-85FD066E-D879-466C-AEC3-F1C542D869F8Q53702293-12C6313A-B3EC-4E78-9D75-3CF601E58D81Q57107876-EA125D01-712F-4DED-9AC9-0D25CBDEDE15Q57192145-BE764300-E3E0-4E34-AB6E-A745DE8FA332Q61808652-CABB3A76-5656-4C64-85F9-741BA368D56BQ64103708-E1186691-B6D2-4502-BF0C-024B60DB041DQ64285361-749C1DF3-B59E-46CA-83E1-0D938C483866Q89669601-E21C69CE-9E2D-486E-BD04-C4FA7F1639ABQ90250610-B63A6651-537F-4964-9DF1-3471E98BD699Q90397145-BEE4A0FA-A0D6-4928-961E-937FEC0DD76DQ90623711-E3E53582-EDCD-49B1-8853-E79A957483D8Q90939002-F66D63DC-1362-4750-BE49-FC6B017DB74FQ91267062-6B982EBA-1556-4CEA-ACD4-D1370104B6B8Q91283016-38DDDF0A-E3B2-48AD-B7CD-362E03346FCBQ91318662-CB4DAE72-377E-4ECD-B360-62F0331EA8D5Q91325494-F811265A-F371-4A44-952A-22373D86A790
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Ulka Vaishampayan
@en
Ulka Vaishampayan
@nl
type
label
Ulka Vaishampayan
@en
Ulka Vaishampayan
@nl
prefLabel
Ulka Vaishampayan
@en
Ulka Vaishampayan
@nl
P31
P496
0000-0001-5800-4571